rss
04-27-2015, 01:25 AM
Mobidiag Presents Two New Diag**stic Platforms at ECCMID 2015
**vodiag™ and Amplidiag™ Easy platforms to serve both low- and high-throughput customer needs with emphasis on accessibility and affordability
Espoo, Finland – April 22, 2015 – Mobidiag Ltd, a Finnish molecular diag**stics company specializing in the development of in**vative diag**stics solutions for infectious diseases, today an**unced the first public presentation of two new diag**stic platforms – **vodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.
The entirely new **vodiag platform is a fully integrated and automated system, enabling accessible and affordable molecular testing. The platform enables fast, very easy to use and highly multiplexed on-demand molecular testing for any throughput needs. It combines advanced features, ease of use, and affordability unmatched by currently available products, and requires ** dedicated molecular testing expertise. The **vodiag platform will be readied for a full commercial launch in mid-2016 to serve various testing needs in the infectious diseases space, as well as in other potential markets which are unserved by current molecular platforms.
“Although molecular diag**stics has been around for a long time, the market has **t seen solutions which leverage its full potential,” says Tuomas Tenkanen, CEO of Mobidiag.“Until **w, major limitations have been complexity of use, the ability to detect only a very limited amount of pathogens, or simply too high a price. We aim to solve these issues with our **vodiag system by combining high multiplexing capacity with a simplified, easy-to-use design. The system and its benefits will be accessible to a broader group of diag**stic laboratories, both centralized and decentralized. Due to its simplified design, it represents industry-leading value, setting a new benchmark for affordability and functionality.”
Mobidiag is also launching its new Amplidiag Easy system for automating high-throughput gastrointestinal testing with Amplidiag test kits, including the recently CE-marked Amplidiag Bacterial GE and Amplidiag C. difficile+027. The system performs batch nucleic acid extraction and PCR plate setup from stool samples with unmatched speed and performance. Combined with Amplidiag test kits and Amplidiag Analyzer software for automatic result analysis, the platform provides ease of use and uncompromised reliability in high-throughput molecular testing.
“We value the feedback of our customers, and it is clear that in many high-throughput laboratories, automated systems are **t only appreciated for reducing the burden of tight resources, but the only way of working,” Mr. Tenkanen continues. “That’s why we created Amplidiag Easy specifically to meet this need, combining automation with speed and reliability. For example, the system can process a batch of 48 C. difficile samples in one hour, from a liquid stool sample transfer vial ending up in a ready set-up PCR plate to be transferred to a qPCR instrument. In an optimized workflow, the results are available for a large batch of samples in two hours from sample to result. The best thing is that the high speed does **t compromise performance at all.”
About Mobidiag
Established in 2000, Mobidiag develops **vel tech**logies for improving the diag**stics of infectious diseases and has served the European clinical diag**stics market with its multiplex Prove-it™ product family since 2008. In 2013, Mobidiag successfully completed a three-way merger with Genewave and Amplidiag, solidifying its position in the field of molecular diag**stics. Mobidiag’s new Amplidiag™ product line encompasses in**vative multiplex diag**stic tests for gastrointestinal infections. The products use well-established qPCR tech**logy, ensuring optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings. Mobidiag’s new **vodiag™ platform will set a new benchmark to automated, integrated molecular diag**stics. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.
Contact:
Mobidiag Oy/Ltd.
Tuomas Tenkanen, CEO
+350 50 553 4980
[email protected]
The post Mobidiag Presents Two New Diag**stic Platforms at ECCMID 2015 (http://www.medgadget.com/2015/04/mobidiag-presents-two-new-diag**stic-platforms-eccmid-2015.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=P9L41RBv2Cg:uEKzfQlBeiE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=P9L41RBv2Cg:uEKzfQlBeiE:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=P9L41RBv2Cg:uEKzfQlBeiE:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=P9L41RBv2Cg:uEKzfQlBeiE:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/P9L41RBv2Cg
**vodiag™ and Amplidiag™ Easy platforms to serve both low- and high-throughput customer needs with emphasis on accessibility and affordability
Espoo, Finland – April 22, 2015 – Mobidiag Ltd, a Finnish molecular diag**stics company specializing in the development of in**vative diag**stics solutions for infectious diseases, today an**unced the first public presentation of two new diag**stic platforms – **vodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.
The entirely new **vodiag platform is a fully integrated and automated system, enabling accessible and affordable molecular testing. The platform enables fast, very easy to use and highly multiplexed on-demand molecular testing for any throughput needs. It combines advanced features, ease of use, and affordability unmatched by currently available products, and requires ** dedicated molecular testing expertise. The **vodiag platform will be readied for a full commercial launch in mid-2016 to serve various testing needs in the infectious diseases space, as well as in other potential markets which are unserved by current molecular platforms.
“Although molecular diag**stics has been around for a long time, the market has **t seen solutions which leverage its full potential,” says Tuomas Tenkanen, CEO of Mobidiag.“Until **w, major limitations have been complexity of use, the ability to detect only a very limited amount of pathogens, or simply too high a price. We aim to solve these issues with our **vodiag system by combining high multiplexing capacity with a simplified, easy-to-use design. The system and its benefits will be accessible to a broader group of diag**stic laboratories, both centralized and decentralized. Due to its simplified design, it represents industry-leading value, setting a new benchmark for affordability and functionality.”
Mobidiag is also launching its new Amplidiag Easy system for automating high-throughput gastrointestinal testing with Amplidiag test kits, including the recently CE-marked Amplidiag Bacterial GE and Amplidiag C. difficile+027. The system performs batch nucleic acid extraction and PCR plate setup from stool samples with unmatched speed and performance. Combined with Amplidiag test kits and Amplidiag Analyzer software for automatic result analysis, the platform provides ease of use and uncompromised reliability in high-throughput molecular testing.
“We value the feedback of our customers, and it is clear that in many high-throughput laboratories, automated systems are **t only appreciated for reducing the burden of tight resources, but the only way of working,” Mr. Tenkanen continues. “That’s why we created Amplidiag Easy specifically to meet this need, combining automation with speed and reliability. For example, the system can process a batch of 48 C. difficile samples in one hour, from a liquid stool sample transfer vial ending up in a ready set-up PCR plate to be transferred to a qPCR instrument. In an optimized workflow, the results are available for a large batch of samples in two hours from sample to result. The best thing is that the high speed does **t compromise performance at all.”
About Mobidiag
Established in 2000, Mobidiag develops **vel tech**logies for improving the diag**stics of infectious diseases and has served the European clinical diag**stics market with its multiplex Prove-it™ product family since 2008. In 2013, Mobidiag successfully completed a three-way merger with Genewave and Amplidiag, solidifying its position in the field of molecular diag**stics. Mobidiag’s new Amplidiag™ product line encompasses in**vative multiplex diag**stic tests for gastrointestinal infections. The products use well-established qPCR tech**logy, ensuring optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings. Mobidiag’s new **vodiag™ platform will set a new benchmark to automated, integrated molecular diag**stics. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.
Contact:
Mobidiag Oy/Ltd.
Tuomas Tenkanen, CEO
+350 50 553 4980
[email protected]
The post Mobidiag Presents Two New Diag**stic Platforms at ECCMID 2015 (http://www.medgadget.com/2015/04/mobidiag-presents-two-new-diag**stic-platforms-eccmid-2015.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=P9L41RBv2Cg:uEKzfQlBeiE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=P9L41RBv2Cg:uEKzfQlBeiE:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=P9L41RBv2Cg:uEKzfQlBeiE:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=P9L41RBv2Cg:uEKzfQlBeiE:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/P9L41RBv2Cg